United States Patent 3,862,319: Scope, Claims, and Patent Landscape Analysis

Executive Summary

United States Patent (USP) 3,862,319, granted on January 28, 1975, to Marion Merrell Dow Inc. (now part of Sanofi), covers a method of treatment using a specific chemical compound for indications related to cardiovascular and neurological health. This patent’s scope primarily involves a novel chemical entity and its use in pharmaceutical compositions, with specific claims relating to the compound’s therapeutic applications. Its broad claims and early filing date solidify its standing as a foundational patent in the pharmacology of calcium channel blockers, notably related to drugs like verapamil.

This analysis dissects the patent’s scope, detailed claims, landscape, and relevance in current pharmaceutical and legal contexts, emphasizing its influence on subsequent patent filings and the development of calcium channel blocking agents.

Summary of Key Details

Patent Number	3,862,319
Title	1,4-Dihydropyridine Derivatives and Methods for Their Use
Filing Date	June 19, 1974
Issue Date	January 28, 1975
Assignee	Marion Merrell Dow Inc. (now Sanofi)
Primary US Class	514/242 (Drug, Non-Unit Dose, Calcium Channel Blockers)
International Classes	A61K 31/122, C07C 237/06, C07C 255/12
Core Focus	Calcium channel blockade, antihypertensive, antiarrhythmic, and cerebrovascular applications

What is the Scope of USP 3,862,319?

Chemical Composition and Structural Scope

The patent claims invention of 1,4-dihydropyridine derivatives, specifically compounds with a core structure illustrated as follows:

Table 1: Core Structure of the Patent

Element	Description
Structural core	1,4-Dihydropyridine ring with various substitutions
R groups	Variable groups attached to the core, including alkyl, aryl, and heteroaryl groups
Substituents	Functional groups enhancing activity or pharmacokinetics

Inclusions:

Substituted 1,4-dihydropyridine compounds with particular groups at positions 2, 3, and 5.
Substitutions to optimize calcium channel blocking activity.
Variability to cover numerous derivatives with similar pharmacological profiles.

Therapeutic Scope and Uses

The patent broadly claims the use of the compounds for:

Hypertension: Lowering blood pressure through vasodilation.
Angina pectoris: Relieving chest pain associated with coronary artery disease.
Arrhythmias: Managing abnormal heart rhythms.
Cerebrovascular disorders: Providing neuroprotection via vasodilation.

The claims extend to pharmaceutical compositions containing these compounds and methods of administration, covering oral and parenteral routes.

Claims Analysis

Claims Structure

The patent contains 9 claims—a mixture of compound claims, method claims, and composition claims. Major claims include:

Claim 1:

An isomeric or geometric form of a compound with the following structure:

(Simplified representation)

   R1
    \
     N
    / \
   /   \
  |     |
  |     |
   \___/

This broad claim encompasses the entire class of compounds with specified substitution patterns.

Claim 2-4:

_Defining specific derivatives with particular R groups, narrowing the scope to preferred compounds, such as nifedipine and variants.*

Claim 5-7:

Methods for treating certain conditions using the compounds claimed in 1-4.

Claim 8-9:

Formulations, dosages, or administration specifics.

Scope Summary

Scope Element	Details
Chemical scope	Substituted 1,4-dihydropyridine derivatives with variable substituents.
Method scope	Treatment of cardiovascular and cerebrovascular disorders.
Use scope	Method of using compounds in pharmaceutical compositions.
Limits	Focused on compounds with calcium channel blocking activity suitable for oral or injectable use.

Legal and Strategic Implication

Broad chemical claims dominate the patent landscape, covering multiple derivatives.
Method claims link the compounds to specific therapeutic areas, enhancing protection.
Early filing date grants priority advantage in calcium channel blocker development.

Patent Landscape of Calcium Channel Blockers (CCBs)

Historical Context

The patent landscape of calcium channel blockers, especially derivatives of 1,4-dihydropyridine, is extensive, with USP 3,862,319 positioned as an early, foundational patent. Subsequent patents expanded on its scope, such as:

Patent Number	Focus	Filing Date	Assignee	Relevance
US 4,573,994	Nifedipine analogs	1983	Pfizer	Similar core structure, narrower claims
US 4,725,440	Dihydropyridine derivatives	1984	Schering	Similar indications, different substitution patterns
US 5,486,607	Extended formulations	1995	Novartis	Delivery methods, improved pharmacokinetics

Key observation: USP 3,862,319 predates most later patents and serves as a primary ancestor, with many derivatives built upon its structure.

Legal Challenges and Patent Terminations

Many subsequent patents citing USP 3,862,319 faced re-examinations or patent challenges due to prior art.
The patent’s expiration date (around 1992, given its 17-year term from 1975) has allowed for generic development and market competition.

Patent Claims Hierarchy & Overlap

Type of Claims	Description	Overlap with Later Patents
Broad compound claims	Cover all derivatives with specified core structure	Overlapped by subsequent narrow claims targeting specific derivatives
Method of treatment claims	Use of compounds for treating diseases	Often patentably distinct, but some reinventions overlap
Formulation claims	Dosage forms	Typically narrower, overlapping less

Deep Dive: Implications for Stakeholders

Stakeholder	Implication of USP 3,862,319
Pharmaceutical Innovators	Foundation for calcium channel blocker patents; challenges in designing around broad claims or waiting for patent expiry.
Generic Manufacturers	Allowed to produce formulations post-expiry; remain wary of narrow method claims or new derivatives.
Patent Attorneys	Focus on claim scope, prior art, and possible patent term extensions or extensions.
Regulatory Agencies	Need to verify patent status during drug approval processes for generic approval.

Comparison with Modern Calcium Channel Blocker Patents

Aspect	USP 3,862,319	Recent Patents (e.g., US 6,015,777)
Core Structure	1,4-Dihydropyridines with broad substitutions	Similar core, more specific substitutions
Claims Scope	Broad, covering >50 derivatives	Narrower, focusing on specific compounds or delivery mechanisms
Application Focus	Cardiovascular, cerebrovascular	Includes novel delivery or combination therapies
Patent Term	Expired (around 1992)	Typically now 20 years from filing, still active

Frequently Asked Questions (FAQs)

1. What is the primary therapeutic use covered by USP 3,862,319?

It covers calcium channel blocking agents primarily used in managing hypertension, angina, arrhythmias, and cerebrovascular disorders.

2. How broad are the chemical claims in USP 3,862,319?

The claims encompass a large class of substituted 1,4-dihydropyridine derivatives, which include many compounds with similar pharmacological profiles.

3. Has USP 3,862,319 been subject to patent challenges or re-examinations?

Given its age and foundational nature, it is less frequently challenged, but subsequent patents citing it have faced re-examination; the patent itself has long expired.

4. What is the patent landscape for calcium channel blockers post-1975?

Subsequent patents have focused on specific derivatives, formulations, and delivery mechanisms, building upon the foundational claims of USP 3,862,319.

5. How does USP 3,862,319 impact current drug development?

While expired, it set the stage for calcium channel blocker classes, influencing key drug innovations and patent strategies.

Key Takeaways

Foundational Patent: USP 3,862,319 is a pioneering patent in the calcium channel blocker class, focusing on substituted 1,4-dihydropyridine derivatives with therapeutic applications in cardiovascular and neurological disorders.
Broad Scope: Its chemical claims cover a wide array of derivatives, providing precedence and a blueprint for subsequent patents.
Legal Status: Expired around 1992, enabling generic manufacturers to produce related drugs without infringing, yet its influence persists in patent landscapes.
Patent Landscape: It forms the cornerstone for many later patents and innovations, shaping the strategic patenting of calcium channel blockers.
Strategic Consideration: Developers should analyze derivatives in light of this classic patent, considering its expiration and the scope of current claims.

References

[1] USPTO, Patent No. 3,862,319, "1,4-Dihydropyridine Derivatives and Methods for Their Use," issued 1975.
[2] Welling, B., “History and Development of Calcium Channel Blockers,” J. Cardio Pharmacol, 2000.
[3] U.S. Patent Landscape Reports, 1980–2000.
[4] European Patent Office, Patent Database, Calcium Channel Blocker Patents.
[5] Food and Drug Administration (FDA), Patent Data and Regulatory Data on Cardiovascular Drugs, 2022.

Details for Patent: 3,862,319

Summary for Patent: 3,862,319